{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-092037","form_type":"8-K","ticker":"CGTX","cik":"0001455365","company_name":"COGNITION THERAPEUTICS INC","filed_at":"2026-08-06T20:18:46+00:00","discovered_at":"2026-08-06T20:20:01.347003+00:00","generated_at":"2026-08-06T20:20:58.464002+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Cognition Therapeutics Q2 2026 net loss $3.9M; advances Phase 3 plan for DLB psychosis","bullets":["Net loss of $3.9M ($0.04 per share) vs $6.7M loss in Q2 2025.","R&D expenses fell to $5.1M from $11.5M; G&A $2.6M vs $2.5M.","Cash $34.8M plus $21.6M grant funds; runway into Q4 2027.","FDA meeting on Phase 3 trial for DLB psychosis; initiation planned for mid-2027.","New composition of matter patent allowed for zervimesine extending protection to 2045."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-092037","json":"https://secwatch.observer/filing/0001104659-26-092037.json","markdown":"https://secwatch.observer/filing/0001104659-26-092037.md","text":"https://secwatch.observer/filing/0001104659-26-092037.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1455365/000110465926092037/0001104659-26-092037-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1455365/000110465926092037/tm2622462d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-06T20:20:58.464002+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}